Delivery Order SPE2DB22D2007-SPE2DB25FJ5BY
- Not listed
- The Defense Logistics Agency awarded a $47,320 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of SKYRIZI 360 MG/2.4 ML on-body injectors. This firm fixed-price contract, which must be completed by September 29, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this delivery order through its existing Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injectors valued at $11,830. This competitively awarded, firm fixed-price delivery order was issued on August 25, 2025, with an ultimate completion date of September 16, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors valued at $11,830.00. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The contract is set to complete by September 18, 2025, with performance executed from AmerisourceBergen's Conshohocken, Pennsylvania headquarters. This delivery order...
- The Defense Logistics Agency awarded a $11,830 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors. The contract, which carries an ultimate completion date of September 29, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $11,830 on September 8, 2025, for the supply of SKYRIZI 180 mg/1.2 ml on-body injectors. This firm fixed-price delivery order, with completion expected by September 29, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of SKYRIZI 360 mg/2.4 mL on-body injectors valued at $11,830.00 under a firm fixed price contract. The order, which is expected to be completed by September 9, 2025, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without a set-aside designation, reflecting the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 180 mg/1.2 mL on-body injector units. This firm fixed-price, non-set-aside delivery order was awarded on September 9, 2025, with an ultimate completion date of September 30, 2025. The pharmaceutical product will be delivered to a location in Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 ml on-body injector devices. This firm fixed price delivery order, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a competitive award with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and falls under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for the supply of SKYRIZI 360 mg/2.4 mL on-body injector units, valued at $12,604.63. This firm fixed price delivery order, with an ultimate completion date of May 30, 2025, represents a competitively awarded procurement with no set-aside designation. The award is performed at the vendor's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen operates as a major...
- The Defense Logistics Agency awarded a delivery order valued at $23,660 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The company,...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5BYDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $23,660 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors. This firm fixed price, competitively awarded contract reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement needs. The delivery order is scheduled for completion by October 9, 2025, with performance to be executed at the contractor's facility in Conshohocken, Pennsylvania. This award was not designated as a set-aside contract. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical commodities to support military healthcare programs globally, including services to the Defense Health Agency and U.S. Coast Guard. The company's substantial contract portfolio with DLA demonstrates its established capability to meet competitive federal procurement standards across diverse therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.7k | 9/18/25 |